Omeros posts Q4 net income of $86.5M; YARTEMLEA approved, zaltenibart deal closed

OMEROS CORP

2026-Q1 EPS reported $0.62 vs consensus -$0.33 ▲ beat (+290.0%)

Q4 2025 net income $86.5M ($1.22/diluted EPS) vs. net loss $31.4M ($0.54) in Q4 2024; full-year net loss narrowed to $3.4M ($0.05) from $156.8M ($2.70).
Closed zaltenibart deal with Novo Nordisk Nov 2025, receiving $240M upfront; repaid $67.1M term loan and $17.1M convertible notes.
FDA approved YARTEMLEA (narsoplimab) for TA-TMA Dec 2025; commercial launch began Jan 2026.
Q4 OMIDRIA royalties $9.2M on $30.7M net sales vs. $10.1M on $33.6M in prior year.
Operating expenses fell to $122.8M in FY25 from $167.0M in FY24, down $44.2M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OMEROS CORP reported fourth quarter and year ended December 31, 2025 results: net income Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, EPS Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million.

Period: fourth quarter and year ended December 31, 2025
Net income: Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million
EPS: Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million
Result: reported results

Exact text from the filing

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results – Conference Call Today at 4:30 p.m. ET

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

OMEROS CORP filing history →

Source: SEC EDGAR

accession 0001437749-26-010634

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.